Human immunoglobulin G

DB00028

biotech approved investigational

Deskripsi

Intravenous immunoglobulin (IVIg) is a mixture of IgG1 and other antibodies derived from healthy human plasma via Cohn fractionation. The purification process includes cold alcohol fractionation, polyethylene glycol precipitation, and ion exchange chromatography. IVIg contains the same distribution of IgG antibody subclasses as is found in the general human population. IgG subclasses are fully represented in the following proportions: 70.3% IgG1, 24.7% IgG2, 3.1% IgG3, and 1.9% IgG4. IVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) >20 hours (mammalian reticulocytes, in vitro).
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

373 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Human immunoglobulin G.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Human immunoglobulin G.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Human immunoglobulin G.
Estrone Estrone may increase the thrombogenic activities of Human immunoglobulin G.
Estradiol Estradiol may increase the thrombogenic activities of Human immunoglobulin G.
Dienestrol Dienestrol may increase the thrombogenic activities of Human immunoglobulin G.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Human immunoglobulin G.
Mestranol Mestranol may increase the thrombogenic activities of Human immunoglobulin G.
Estriol Estriol may increase the thrombogenic activities of Human immunoglobulin G.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Human immunoglobulin G.
Quinestrol Quinestrol may increase the thrombogenic activities of Human immunoglobulin G.
Hexestrol Hexestrol may increase the thrombogenic activities of Human immunoglobulin G.
Tibolone Tibolone may increase the thrombogenic activities of Human immunoglobulin G.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Human immunoglobulin G.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Human immunoglobulin G.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Human immunoglobulin G.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Human immunoglobulin G.
Zeranol Zeranol may increase the thrombogenic activities of Human immunoglobulin G.
Equol Equol may increase the thrombogenic activities of Human immunoglobulin G.
Promestriene Promestriene may increase the thrombogenic activities of Human immunoglobulin G.
Methallenestril Methallenestril may increase the thrombogenic activities of Human immunoglobulin G.
Epimestrol Epimestrol may increase the thrombogenic activities of Human immunoglobulin G.
Moxestrol Moxestrol may increase the thrombogenic activities of Human immunoglobulin G.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Human immunoglobulin G.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Human immunoglobulin G.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Human immunoglobulin G.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Human immunoglobulin G.
Biochanin A Biochanin A may increase the thrombogenic activities of Human immunoglobulin G.
Formononetin Formononetin may increase the thrombogenic activities of Human immunoglobulin G.
Estetrol Estetrol may increase the thrombogenic activities of Human immunoglobulin G.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Human immunoglobulin G.
Omalizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Omalizumab.
Adalimumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Adalimumab.
Abciximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Abciximab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Gemtuzumab ozogamicin.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Indium In-111 satumomab pendetide.
Infliximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Infliximab.
Trastuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Trastuzumab.
Rituximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Rituximab.
Basiliximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Basiliximab.
Muromonab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Muromonab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Digoxin Immune Fab (Ovine).
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ibritumomab tiuxetan.
Tositumomab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tositumomab.
Alemtuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Alemtuzumab.
Capromab pendetide The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Capromab pendetide.
Efalizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Efalizumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Antithymocyte immunoglobulin (rabbit).
Natalizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Natalizumab.
Palivizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Palivizumab.
Daclizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Daclizumab.
Bevacizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bevacizumab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Technetium Tc-99m arcitumomab.
Eculizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Eculizumab.
Panitumumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Panitumumab.
Ranibizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ranibizumab.
Galiximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Galiximab.
Pexelizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Pexelizumab.
Afelimomab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Afelimomab.
Epratuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Epratuzumab.
Bectumomab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bectumomab.
Oregovomab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Oregovomab.
IGN311 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with IGN311.
Adecatumumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Adecatumumab.
Labetuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Labetuzumab.
Matuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Matuzumab.
Fontolizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Fontolizumab.
Bavituximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bavituximab.
CR002 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with CR002.
Rozrolimupab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Rozrolimupab.
Girentuximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Girentuximab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Obiltoxaximab.
XTL-001 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with XTL-001.
NAV 1800 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with NAV 1800.
Briakinumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Briakinumab.
Otelixizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Otelixizumab.
AMG 108 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with AMG 108.
Iratumumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Iratumumab.
Enokizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Enokizumab.
Ramucirumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ramucirumab.
Farletuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Farletuzumab.
Veltuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Veltuzumab.
Ustekinumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ustekinumab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Trastuzumab emtansine.
PRO-542 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with PRO-542.
TNX-901 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with TNX-901.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Inotuzumab ozogamicin.
RI 624 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with RI 624.
Stamulumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with MYO-029.
CT-011 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with CT-011.
Leronlimab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Leronlimab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Glembatumumab vedotin.
Olaratumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Olaratumab.
IPH 2101 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with IPH 2101.
TB-402 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with TB-402.
Caplacizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Caplacizumab.
IMC-1C11 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with IMC-1C11.
Eldelumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Eldelumab.
Lumiliximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lumiliximab.
Canakinumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Canakinumab.

Target Protein

High affinity immunoglobulin gamma Fc receptor I FCGR1A
Putative high affinity immunoglobulin gamma Fc receptor IB FCGR1BP
Low affinity immunoglobulin gamma Fc region receptor II-a FCGR2A
Low affinity immunoglobulin gamma Fc region receptor II-b FCGR2B
Low affinity immunoglobulin gamma Fc region receptor II-c FCGR2C
Low affinity immunoglobulin gamma Fc region receptor III-A FCGR3A
Low affinity immunoglobulin gamma Fc region receptor III-B FCGR3B
Complement C3 C3
Complement C4-A C4A
Complement C4-B C4B
Complement C5 C5

Referensi & Sumber

Synthesis reference: Wolfgang Stephan, "Production of intravenously applicable native human immune globulin having a normal half-life." U.S. Patent US4082734, issued July, 1970.
Artikel (PubMed)
  • PMID: 20970960
    Bayry J, Fournier EM, Maddur MS, Vani J, Wootla B, Siberil S, Dimitrov JD, Lacroix-Desmazes S, Berdah M, Crabol Y, Oksenhendler E, Levy Y, Mouthon L, Sautes-Fridman C, Hermine O, Kaveri SV: Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun. 2011 Feb;36(1):9-15. doi: 10.1016/j.jaut.2010.09.006. Epub 2010 Dec 9.
  • PMID: 17911465
    Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.
  • PMID: 16998749
    Stangel M, Pul R: Basic principles of intravenous immunoglobulin (IVIg) treatment. J Neurol. 2006 Sep;253 Suppl 5:V18-24.
  • PMID: 12032582
    Emmi L, Chiarini F: The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders. Neurol Sci. 2002 Apr;23 Suppl 1:S1-8.
Link

Contoh Produk & Brand

Produk: 178 • International brands: 1
Produk
  • Alyglo
    Liquid • 100 mg/1mL • Intravenous • US • Approved
  • Asceniv
    Liquid • 5 g/50mL • Intravenous • US • Approved
  • Bivigam
    Injection, solution • 1 g/10mL • Intravenous • US • Approved
  • Bivigam
    Injection, solution • 5 g/50mL • Intravenous • US • Approved
  • Bivigam
    Injection, solution • 10 g/100mL • Intravenous • US • Approved
  • Bivigam
    Injection, solution • 5 g/50mL • Intravenous • US • Approved
  • Bivigam
    Injection, solution • 10 g/100mL • Intravenous • US • Approved
  • Carimune Nanofiltered
    Injection, powder, lyophilized, for solution • 3 g/1 • Intravenous • US • Approved
Menampilkan 8 dari 178 produk.
International Brands
  • ClairYg

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul